Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Liabilities and Shareholders Equity (2024 - 2025)

BioAge Labs (BIOA) has disclosed Liabilities and Shareholders Equity for 2 consecutive years, with $294.9 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 17.68% to $294.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Dec 2025, up 81.99% year-over-year, with the annual reading at $294.9 million for FY2025, 17.68% down from the prior year.
  • Liabilities and Shareholders Equity hit $294.9 million in Q4 2025 for BioAge Labs, down from $305.1 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $358.2 million in Q4 2024 to a low of $294.9 million in Q4 2025.